Repeated SARS-CoV-2 infections still threaten public health around the world. Researchers are still committed to carrying out research on vaccines, small molecular antiviral drugs, and neutralizing antibodies to find more effective means of prevention and treatment for the infection of various mutants of novel coronavirus. Among them, neutralizing antibodies have the advantages of clear action mechanism, good safety, and convenience for large-scale production, so they are one of the therapeutic class of drugs with best potential to treat COVID-19. The research and development projects for SARS-CoV-2 neutralizing antibodies have been developing rapidly both at home and abroad. This paper briefly introduces the research status of SARS-CoV-2 neutralizing antibodies, focusing on providing special considerations for pharmaceutical evaluation of these class of drugs in combination with the practice of drug evaluation to promote the industrialization of the same class of domestic products as soon as possible.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |